Literature DB >> 25140952

FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.

Edward Cox1, Katherine Laessig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25140952     DOI： 10.1056/NEJMp1314385

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Bedaquiline.

Authors:  Sebastiaan C Goulooze; Adam F Cohen; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

3.  Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis.

Authors:  Alvaro A Ordonez; Laurence S Carroll; Sudhanshu Abhishek; Filipa Mota; Camilo A Ruiz-Bedoya; Mariah H Klunk; Alok K Singh; Joel S Freundlich; Ronnie C Mease; Sanjay K Jain
Journal:  ACS Infect Dis       Date:  2019-07-29       Impact factor: 5.084

4.  Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.

Authors:  Xianglong Hu; Baojie Wan; Yang Liu; Jiayi Shen; Scott G Franzblau; Tianyu Zhang; Ke Ding; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2019-02-21       Impact factor: 4.345

5.  A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosis.

Authors:  Liqin Wang; Miao Xu; Noel Southall; Wei Zheng; Shuishu Wang
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

6.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.

Authors:  Jan-Willem C Alffenaar; Mathieu Bolhuis; Kai van Hateren; Marieke Sturkenboom; Onno Akkerman; Wiel de Lange; Ben Greijdanus; Tjip van der Werf; Daan Touw
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

8.  NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G.

Authors:  Sohini Chakraborti; Neha Khare; Sumana Das; Saqib Kidwai; Rania Bouzeyen; Tannu Priya Gosain; Assirbad Behura; Chhuttan Lal Meena; Rohan Dhiman; Makram Essafi; Avinash Bajaj; Deepak Kumar Saini; Narayanaswamy Srinivasan; Dinesh Mahajan; Ramandeep Singh
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

9.  Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.

Authors:  Peter M Keller; Rico Hömke; Claudia Ritter; Giorgia Valsesia; Guido V Bloemberg; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

10.  Narrow-Spectrum Antibacterial Agents.

Authors:  Roberta J Melander; Daniel V Zurawski; Christian Melander
Journal:  Medchemcomm       Date:  2017-11-06       Impact factor: 3.597
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.